EHA 2019 | Current CML treatments: which TKI to choose?

Name: Current CML treatments: which TKI to choose?
Uploaded: 2019-06-13T00:00:00.000Z
Duration: 2 min 17 s
Description: Gianantonio Rosti, MD, Institute of Hematology 'Seragnoli', Bologna, Italy, discusses the current landscape of chronic myeloid leukemia (CML) treatment, as well as the importance of consistent long-term monitoring. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

Gianantonio Rosti • 13 Jun 2019

EHA 2019

Chronic Myeloid Leukemia Leukemia Bosutinib Dasatinib Imatinib Nilotinib Ponatinib

Gianantonio Rosti, MD, Institute of Hematology ‘Seragnoli’, Bologna, Italy, discusses the current landscape of chronic myeloid leukemia (CML) treatment, as well as the importance of consistent long-term monitoring. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.